Avandia (rosiglitazone maleate) in combination with insulin
17 August 2007
The TGA approved Product Information for Avandia (rosiglitazone maleate) has changed
so that rosiglitazone maleate should not be added to therapy in patients receiving
insulin, as there may be an increased risk of heart failure and myocardial ischaemia
in this group.
Insulin can be added to therapy in patients established on rosiglitazone maleate.
The PBS listing for rosiglitazone will be amended to reflect these changes on 1 October 2007, but prescribers are advised to adopt this new guidance immediately.
Should you require any further information please contact the PBS Information Line on 1800 020 613 or GlaxoSmithKline on 1800 033 109.